Rates of persistent viremia (PV), defined as a detectable hepatitis c (HCV) viral load after 4 weeks of direct-acting antiviral (DAA) therapy, were low (5.7%) in a real-world cohort of 983 patients. High sustained virologic response (SVR) rates were achieved both in patients with PV (92.9%) and those with rapid virologic response (RVR) (96.5%), without significant differences.

This case series describes the safety and effectiveness outcomes of patietns requiring HCV DAA tablet manipulation. This data along with a comprehensive review of other reports of DAA manipulation demonstrate the safety and efficacy of tablet manipulation.

This report discusses reasons anticancer therapies may need to be initiated on admission, challenges of doing so, perspectives and experiences from 3 unique HSSPs on addressing these challenges, and finally, best practice recommendations in managing high cost oral anticancer therapies for admitted patients.

The purpose of this article is to describe medication alternatives available for use in patients with certain bleeding disorders during the intranasal desmopressin recall. Intranasal desmopressin plays a key role in treatment of these patients and the recall is expected to impact availability until mid to late 2023. We hope the details of the article can help other institutions select the best treatment alternative for their patients during this time.

This study found that integrating a pharmacist into clinic significantly shortened time from treatment decision to shipment for LDD drugs, partially overcoming access barriers. Additionally, access to LDDs was still slower than non-LDDs as they cannot be fully integrated into clinic workflow. The integrated specialty pharmacy program adds value to patient access and outperforms LDDs, challenging the value of LDD networks beyond medical economics.

This is a phase IV single-arm study prospectively evaluating the safety and efficacy of apixaban for primary prevention of VTE in patients with MM. The study found that during the 6 month evaluation no patients experienced major hemorrhagic events, MI, stroke, or death. Three patients did have non-major events that were medically managed and one patient discontinued therapy because of an allergic reaction to apixaban.

Ivosidenib is the first approved oral, targeted, small molecule inhibitor of the isocitrate dehydrogenase 1 (IDH1) mutation seen in acute myeloid leukemia. This review article discusses the clinical trials and dose escalation studies conducted to secure the U.S. Food and Drug Administration approval.

This study looked at 21 acute myeloid leukemia patients who had received a hematopoietic cell transplant and experienced relapsed disease. Each patient underwent salvage therapy with a venetoclax- based treatment regimen. Nineteen patients were assessed for treatment response and 12 of the 19 patients responded to venetoclax-based salvage therapy, leading to a 63.2% response rate.

Immunomodulatory therapies for multiple myeloma can increase patient risk for venous thromboembolism (VTE). This phase IV single-arm study assessed the rate of symptomatic VTE over 6 months in 50 patients with multiple myeloma receiving immunomodulatory therapy and apixaban for primary prevention. No patients experienced symptomatic VTE or a major hemorrhage and 3 patients experienced clinically relevant non-major hemorrhage but were able to resume apixaban after medical management.

In this initiative, we evaluated outcomes following prescription of specialty dermatology medications in biologic-naïve patients. Of the 28 prescriptions evaluated, median time to approval was 9 days, with delays resulting from the need for a pharmacist to ascertain clinical data such as disease severity and treatment history.